Navigation Links
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Date:6/12/2008

s lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung or gastrointestinal cancers. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development.

About Blinatumomab

Blinatumomab, also known as MT103 or MEDI-538, is a BiTE(R) antibody being developed with the intent to treat certain types of B cell lymphomas. In February 2006, the U.S. Food and Drug Administration approved an orphan drug designation for blinatumomab for certain types of indolent B cell lymphoma. Blinatumomab also received orphan drug designation from the European Medicines Agency for mantle cell lymphoma and chronic lymphocytic leukemia. Blinatumomab specifically targets the CD19 antigen, which is present on B cells and B cell-derived tumors, but not on other types of blood cells or healthy tissues.

Micromet and MedImmune are developing blinatumomab under the terms of a 2003 agreement in which MedImmune has obtained exclusive rights for blinatumomab in North America. Micromet has retained the rights to blinatumomab outside of North America.

About Micromet, Inc.

Micromet, Inc. (http://www.micromet-inc.com) is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab, also known as MT103, is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own immune system to eliminate cancer
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Micromet Announces Changes in Management Team
10. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
11. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that surveyed ... a greater effect on quality of life is ... the high level of subjectivity and variability of ... thought leaders state that it is difficult to ...
(Date:5/19/2013)... 2013 Claret Medical, Inc. announced the publication of ... et al., Histopathology of Embolic Debris Captured ... in Circulation, May 7 th this research is the ... Rotterdam, the Netherlands and the pathology team of ... Pathology Institute, Gaithersburg, Maryland.  This is the ...
(Date:5/19/2013)... Fla. , May 19, 2013  The ... and low temperature radiofrequency (RF) energy is effective ... eliminates or reduces the need for medication 10 ... assessment presented today at the Digestive Disease Week ... Orlando, Florida . "The ...
Breaking Medicine Technology:For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3
... Increases in deaths from opioid drugs such as OxyContin may ... the news, according to a study from Children,s Hospital Boston and ... patterns of opioid deaths and patterns of news coverage between 1999 ... It found that spikes in media coverage often preceded an increase ...
... , , KIBBUTZ SHAMIR, Israel, Nov. 18 Shamir ... a leading provider of innovative products and technology to the ... third quarter ended September 30, 2009. , For the quarter ... $36.1 million for the third quarter of 2008. Gross ...
Cached Medicine Technology:Breaking the News, or Fueling the Epidemic? News Coverage of Opioid-Related Deaths Often Precede an Increase in Deaths, Study Finds 2Breaking the News, or Fueling the Epidemic? News Coverage of Opioid-Related Deaths Often Precede an Increase in Deaths, Study Finds 3Breaking the News, or Fueling the Epidemic? News Coverage of Opioid-Related Deaths Often Precede an Increase in Deaths, Study Finds 4Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results 10
(Date:5/21/2013)... 21, 2013 Dr. James C. Wittig, ... of the Sarcoma Division of the John Theurer Cancer ... has been named one of the top 13 Orthopedic ... Dr. Wittig is one of approximately 125 surgeons ... was created by surveying thought leaders in the field ...
(Date:5/21/2013)... Brunswick Laboratories, Inc. announces that AOAC ... standardization of validated analytical methods, has approved the ... the USDA, as a First Action Official MethodSM ... after extensive review by an AOAC expert review ... U.S. Department of Agriculture. , Jin Ji, PhD., ...
(Date:5/21/2013)... According to the Center for Disease Control and ... year. Over 800,000 of these bites require medical attention, ... should be aware of the danger that dog bites pose ... and children may sustain more serious injuries than an adult. ... the ages of 5 and 9 are at the greatest ...
(Date:5/20/2013)... 2013 USA Book News announced Monday ... Peak Performance" won the top honor in its 2013 ... over a multitude of international titles published from 2011-2013, ... acclaim from both mainstream and new age audiences looking ... and spiritually. , “The Infinity Zone” is ...
(Date:5/20/2013)... Southfield, Michigan (PRWEB) May 21, 2013 This ... National Dog Bite Prevention Week (May 19th-May 25th) is an ... dog bite attacks and by encouraging dog owners to properly ... a dog. , Michigan dog bite lawyers at ... animal attacks in cases throughout Michigan. The personal injury law ...
Breaking Medicine News(10 mins):Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:AOAC International Approves ORAC as First Action Official Method 2Health News:Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2
... Hospital is the only pediatric hospital in the ... The American Nurses,Credentialing Center (ANCC) has awarded DMC ... nursing. Recognized as one of the,highest distinctions a ... five,percent of all U.S. hospitals have achieved this ...
... April 17 The Connecticut,Hospice, Inc., the nation,s ... from its first class of The Norma F. ... by a,generous grant merited by the Connecticut Hospice,s ... for education and,training in hospice and palliative care. ...
... explain antidepressants, effectiveness , , THURSDAY, April 17 (HealthDay News) ... old brain cells to their more plastic youthful condition ... only provides a possible new explanation for the antidepressant ... prospect that it could be used to treat other ...
... drinkers and heavy,smokers develop Alzheimer,s disease years earlier ... smoke heavily, according to research that,will be presented ... Meeting in Chicago, April 12-19, 2008., "These ... we can,reduce or eliminate heavy smoking and drinking, ...
... N.Y., April 17 CTG (Nasdaq: CTGX ),an ... that it would release its 2008 first quarter,financial results ... company,will hold a conference call to discuss its financial ... 10:00 a.m. Eastern Time. CTG,Chairman and Chief Executive Officer ...
... Calif., April 17 The National Center for,Autism ... for autism research, education and family support,services has ... are,flocking to NCARE resulting from the announcement to ... that families desperately need centralized,autism resources., Soonhee ...
Cached Medicine News:Health News:Children's Hospital of Michigan Awarded Prestigious Magnet Status 2Health News:The Norma F. Pfriem International Fellowship in Hospice and Palliative Care Nursing 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:Alzheimer's Starts Earlier for Heavy Drinkers, Smokers 2Health News:CTG Announces 2008 First Quarter Conference Call and Webcast Information 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2
... Visionblue is a staining solution for ... required for performing a safe phaco-emulsification ... lens capsule may result in an ... risk of radial capsule tears and ...
Rhex-ID (Trypan Blue 0.8 mg)....
Unmatched versatility for hemostasis wherever needed. Can be applied to suit your needs....
Auto refractometer....
Medicine Products: